NEWYou can now listen to Fox News articles!
Chocolate sales are rising faster among people using weight-loss drugs than in the rest of the population, according to a new report.
Swiss chocolatier Lindt & Sprüngli cited data countering predictions that GLP-1 drugs would reduce interest in sweets.
Semaglutide medications, like Ozempic and Wegovy, mimic the natural hormone GLP‑1 (glucagon‑like peptide‑1), while tirzepatides (such as Mounjaro and Zepbound) target both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors.
WEIGHT-LOSS MEDICATIONS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS
While consumers taking these drugs may be cutting back on high-calorie foods like pasta and pizza, they are still looking for indulgence, Chief Executive Adalbert Lechner said during a recent news conference.
“They are upgrading to premium products,” Lechner said. “Less is more — small rewards with a moment of bliss rather than mindless munching.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
An internal company study found that 15% of U.S. households use GLP-1s medications — and those households accounted for roughly 17.5% of chocolate sales in the dataset. Lindt also reported that U.S. premium chocolate sales rose nearly 17% among GLP-1 users in 2025, compared with about 6.5% growth among non-users.
OPRAH JOINS WAVE OF CELEBRITIES WHO REVEALED DRAMATIC WEIGHT LOSS IN 2025
“Consumers worldwide continue to seek quality and moments of indulgence,” Lechner said in a news release.
However, a 2025 study from Cornell University and Numerator suggests a different trend. That report found GLP-1 users cut spending on calorie-dense snacks by about 10%, with “similarly large decreases” in sweets, baked goods and cookies.
CLICK HERE FOR MORE HEALTH STORIES
“The main pattern is a reduction in overall food purchases,” said Sylvia Hristakeva, an assistant professor and co-author of the Cornell study. “Only a small number of categories show increases, and those are modest relative to the overall decline.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Despite these findings, Lechner said he does not view the popularization of weight-loss drugs as a threat to business.
Analysts had expected the introduction of GLP-1 pills to negatively affect the food industry over the next few years.
Experts predict that the oral versions of the weight-loss medications will expand the market to include more men and younger patients.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Fox News Digital reached out to pharmaceutical developers of GLP-1 medications for comment.
Read the full article here
